Follicular Lymphoma
Showing 26 - 50 of 6,008
Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,
Completed
- Grade 3a Follicular Lymphoma
- +9 more
- Laboratory Biomarker Analysis
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 31, 2023
Lymphoma, Follicular, Follicular Lymphoma Trial in Saint Louis (Mosunetuzumab, Polatuzumab vedotin)
Recruiting
- Lymphoma, Follicular
- Follicular Lymphoma
- Mosunetuzumab
- Polatuzumab vedotin
-
Saint Louis, MissouriWashington University School of Medicine
Nov 14, 2022
Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,
Not yet recruiting
- Non-hodgkin Lymphoma
- +9 more
- CD79b-19 CAR T cells
- +2 more
-
Boston, MassachusettsMassachusetts General Hospital
Sep 6, 2023
Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2
Active, not recruiting
- Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma
- +22 more
- External Beam Radiation Therapy
- Orbital Radiation
-
Houston, TexasM D Anderson Cancer Center
Dec 9, 2022
B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,
Recruiting
- B-Cell Non-Hodgkin Lymphoma
- +7 more
- Acalabrutinib
- Axicabtagene Ciloleucel
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Dec 9, 2022
Indolent Non-hodgkin Lymphoma Trial in Shanghai (IBI376)
Active, not recruiting
- Indolent Non-hodgkin Lymphoma
-
Shanghai, ChinaRuijin hospital, school of medicine, Shanghai jiao tong universi
Oct 3, 2022
Relapsed/Refractory Follicular Lymphoma With EZH2 Trial in Shanghai (Tazemetostat)
Not yet recruiting
- Relapsed/Refractory Follicular Lymphoma With EZH2
-
Shanghai, Shanghai, ChinaShanghai Cancer Center
Jul 20, 2022
Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1
Active, not recruiting
- Ann Arbor Stage I Grade 1 Follicular Lymphoma
- +3 more
- Clinical Observation
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Follicular Lymphoma Trial in Miami (Loncastuximab tesirine, Rituximab)
Recruiting
- Follicular Lymphoma
- Loncastuximab tesirine
- Rituximab
-
Miami, FloridaUniversity of Miami
Jul 11, 2022
Relapsed/Refractory Follicular Lymphoma Trial in Nashville (Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine)
Recruiting
- Relapsed/Refractory Follicular Lymphoma
- Axicabtagene Ciloleucel
- +8 more
-
Denver, Colorado
- +6 more
Dec 2, 2022
Refractory Follicular Lymphoma, Relapsed Follicular Lymphoma Trial in Washington, Hackensack, Seattle (Ibrutinib, Venetoclax)
Recruiting
- Refractory Follicular Lymphoma
- Relapsed Follicular Lymphoma
-
Washington, District of Columbia
- +2 more
Jul 6, 2022
Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a Trial in Heidelberg (Standard, Experimental)
Recruiting
- Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a
- Standard
- Experimental
-
Heidelberg, GermanyUniversity Hospital Heidelberg
Jul 10, 2022
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Palo Alto (Ibrutinib, Radiation
Active, not recruiting
- Grade 1 Follicular Lymphoma
- +6 more
- Ibrutinib
- +2 more
-
Palo Alto, CaliforniaStanford University, School of Medicine
Jun 13, 2022
Follicular Lymphoma, Small Lymphocytic Lymphoma Trial in Fort Myers, Saint Petersburg, Nashville (Ublituximab, Umbralisib)
Terminated
- Follicular Lymphoma
- Small Lymphocytic Lymphoma
-
Fort Myers, Florida
- +2 more
Jul 20, 2022
Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma Trial in United Kingdom (Epcoritamab, Lenalidomide, Rituximab)
Not yet recruiting
- Relapsed Follicular Lymphoma
- Refractory Follicular Lymphoma
- Epcoritamab
- +10 more
-
Aberdeen, United Kingdom
- +24 more
Apr 28, 2023
Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Duarte (Tazemetostat, Ublituximab, Umbralisib)
Not yet recruiting
- Recurrent Follicular Lymphoma
- Refractory Follicular Lymphoma
- Tazemetostat
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jul 31, 2022
COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in
Not yet recruiting
- Follicular Lymphoma
- Cellular immunity vs SARS-CoV-2
- +6 more
-
Alessandria, IT, Italy
- +13 more
Oct 10, 2023
Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Grade 1
Active, not recruiting
- Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- +18 more
- Anti-ICOS Monoclonal Antibody MEDI-570
- +2 more
-
Duarte, California
- +22 more
Jan 18, 2023
Relmacabtagene Autoleucel in Hematologic Malignancies
Not yet recruiting
- Lymphoma, B-Cell
- +2 more
- Relmacabtagene Autoleucel
-
Beijing, Beijing, China
- +1 more
Nov 15, 2023
Follicular Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma Trial in New York (Tazemetostat Pill)
Not yet recruiting
- Follicular Lymphoma
- +3 more
- Tazemetostat Pill
-
New York, New YorkWeill Cornell Medicine/NewYork-Presbyterian Hospital
Jun 28, 2023
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial (BGB-21447)
Not yet recruiting
- Relapsed Non-Hodgkin Lymphoma
- +6 more
- (no location specified)
Apr 12, 2023